| Cyprotex and DSEC invite you to our 8th North American Drug Discovery Workshop | |||||
 |
|||||
| 8th North American Drug Discovery Workshop April 12, 2012 8:30am – 5:30pm |
|||||
 |
|||||
 |
|||||
 |
||
| Discovery to IND: De-Risking Drug Discovery Programs Early | ||
|
||
| Ernie Bush, Ph.D. Vice President of Collaborative Projects, Drug Safety Executive Council (DSEC) Industry Trends in Predictive Toxicology Technologies |
||
|
||
| Steven A. Kates, Ph.D. Vice President of R & D, Ischemix Outsourcing in Drug Development – From the Bench to Market |
||
|
||
| Simon Messner, Ph.D. Toxicology, InSphero Toxicology Applications of 3D Liver Models |
||
|
||
| Ania Knap, Ph.D. President and CSO, New England PharmAssociates The Benefits of Being a Virtual Company |
||
|
||
| Joe Senn, Ph.D. Lead Investigative Toxicology, Millennium Pharmaceuticals Evaluating In Vivo Hepatotoxicity Threat with Multiple Endpoint Screening in Lead Optimization to De-Risk Transition to Development |
||
|
||
| Rod Cole, Ph.D. Director, Analytical Sciences, Cerulean Pharma Assessing the Utility of In Vitro ADME Assays in Predicting Nanoparticle Formulation Performance |
||
|
||
| Simon Hirst, Ph.D. Founder and CEO, Sygnature Discovery A Networked Model for the Delivery of Integrated Drug Discovery |
||
|
||
| Arthur "Buzz" Brown, Ph.D. Founder and CEO, ChanTest A New Look at Nonclinical Cardiac Risk Assessment |
||
|
||
| Katya Tsaioun, Ph.D. CSO, Cyprotex gADME: Genomic ADME for Repositioning Compounds Failed in Human Trials and Genomic Profiling of Early Candidates for Selection of Subjects for Clinical Trials |
||
|
||
